On January 6, 2022 ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, reported its participation in the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10–13, 2022 (Press release, ProMIS Neurosciences, JAN 6, 2022, View Source [SID1234598358]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the pre-recorded presentation will be made available at 7:00 AM ET on Monday, January 10th and will be available under "News and Events" in the Investors section of the company’s website at View Source

ProMIS Executive Chairman and CEO, Eugene Williams, will provide an update on the company with an overview of its unique technology platform that has enabled ProMIS to develop a broad portfolio of antibody candidates selectively targeting toxic misfolded proteins in multiple neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD), among others. In addition, the presentation will focus on PMN310, ProMIS’ oligomer-selective lead antibody for AD, currently in late preclinical development/IND enabling studies.